Understanding the effectiveness of natural compound mixtures in cancer through their molecular mode of action

International Journal of Molecular Sciences

Volumn 18, Issue 3, 2017, Pages

  Aung, Thazin Nwe ^a   Qu, Zhipeng ^a   Kortschak, R Daniel ^a   Adelson, David L ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Apoptosis; Cancer; Chemosensitization; Metal derivatized natural compounds; MicroRNA; Natural compound mixtures

Indexed keywords

ABC TRANSPORTER; ALKALOID; ANTINEOPLASTIC AGENT; CHIKUSETSU SAPONIN; CURCUMIN; CYCLOOXYGENASE 2; DIOSGENIN; DITERPENOID; FLAVONOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; NATURAL PRODUCT; OXYMATRINE; SAPONIN; TETRANDRINE; TRANSCRIPTOME; HERBACEOUS AGENT;

APOPTOSIS; BIOLOGICAL ACTIVITY; CANCER GROWTH; CELL CYCLE ARREST; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMOSENSITIZATION; CHINESE MEDICINE; CYTOTOXICITY; DNA DAMAGE; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION; HUMAN; MALIGNANT NEOPLASM; MICROARRAY ANALYSIS; NONHUMAN; PROTEOMICS; REVIEW; SOPHORA FLAVESCENS; ANIMAL; CHEMISTRY; DRUG EFFECTS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; DRUGS, CHINESE HERBAL; HUMANS;

EID: 85015973785     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18030656     Document Type: Review

References (135)

1. Newman, D.J.; Cragg, G.M.; Snader, K.M. Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod. 2003, 66, 1022-1037. [CrossRef] [PubMed]
2. Alberts, B.; Johnson, A.; Lewis, J.; Raff, M.; Roberts, K.; Walter, P. Programmed Cell Death (Apoptosis). In Molecular Biology of the Cell, 4th ed.; Garland Science: New York, NY, USA, 2002.
3. Wajant, H. The Fas signaling pathway: More than a paradigm. Science 2002, 296, 1635-1636. [CrossRef] [PubMed]
4. Galluzzi, L.; Vitale, I.; Abrams, J.; Alnemri, E.; Baehrecke, E.; Blagosklonny, M.; Dawson, T.M.; Dawson, V.; El-Deiry, W.; Fulda, S. Molecular definitions of cell death subroutines: Recommendations of the Nomenclature Committee on Cell Death 2012. Cell. Death Differ. 2012, 19, 107-120. [CrossRef] [PubMed]
5. Mehlen, P.; Bredesen, D.E. Dependence receptors: From basic research to drug development. Sci. Signal. 2011, 4, mr2. [CrossRef] [PubMed]
6. Wong, R. Apoptosis in cancer: From pathogenesis to treatment. J. Exp. Clin. Cancer Res. 2011, 30, 87. [CrossRef] [PubMed]
7. Chen, R.; Wang, H.; Liang, B.; Liu, G.; Tang, M.; Jia, R.; Fan, X.; Jing, W.; Zhou, X.; Wang, H. Downregulation of ASPP2 improves hepatocellular carcinoma cells survival via promoting BECN1-dependent autophagy initiation. Cell Death Dis. 2016, 7, e2512. [CrossRef] [PubMed]
8. Codogno, P.; Meijer, A.J. Atg5: More than an autophagy factor. Nat. Cell Biol. 2006, 8, 1045-1046. [CrossRef] [PubMed]
9. Schmitt, C.A.; McCurrach, M.E.; de Stanchina, E.; Wallace-Brodeur, R.R.; Lowe, S.W. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 1999, 13, 2670-2677. [CrossRef] [PubMed]
10. Dive, C.; Hickman, J. Drug-target interactions: Only the first step in the commitment to a programmed cell death? Br. J. Cancer 1991, 64, 192. [PubMed]
11. Chai, S.; To, K.; Lin, G. Circumvention of multi-drug resistance of cancer cells by Chinese herbal medicines. Chin. Med. 2010, 5, 26. [CrossRef] [PubMed]
12. Yu-Jen, C. Potential role of tetrandrine in cancer therapy. Acta Pharmacol. Sin. 2002, 23, 1102-1106.
13. Tian, H.; Pan, Q. A comparative study on effect of two bisbenzylisoquinolines, tetrandrine and berbamine, on reversal of multidrug resistance. Acta Pharm. Sin. 1997, 32, 245-250.
14. Choi, S.-U.; Park, S.-H.; Kim, K.-H.; Choi, E.-J.; Kim, S.; Park, W.-K.; Zhang, Y.-H.; Kim, H.-S.; Jung, N.-P.; Lee, C.-O. The bis benzylisoquinoline alkaloids, tetrandine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein. Anti Cancer Drugs 1998, 9, 255-262. [CrossRef] [PubMed]
15. Kang, J.; Kim, E.; Kim, W.; Seong, K.M.; Youn, H.; Kim, J.W.; Kim, J.; Youn, B. Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines. J. Biol. Chem. 2013, 288, 27343-27357. [CrossRef] [PubMed]
16. Graw, S.; Meier, R.; Minn, K.; Bloomer, C.; Godwin, A.K.; Fridley, B.; Vlad, A.; Beyerlein, P.; Chien, J. Robust gene expression and mutation analyses of RNA-sequencing of formalin-fixed diagnostic tumor samples. Sci. Rep. 2015, 5, 12335. [CrossRef] [PubMed]
17. Kaufmann, S.H.; Earnshaw,W.C. Induction of apoptosis by cancer chemotherapy. Exp. Cell Res. 2000, 256, 42-49. [CrossRef] [PubMed]
18. Espinosa, E.; Zamora, P.; Feliu, J.; Barón, M.G. Classification of anticancer drugs-A new system based on therapeutic targets. Cancer Treat. Rev. 2003, 29, 515-523. [CrossRef]
19. Manson, M.M. Cancer prevention-the potential for diet to modulate molecular signalling. Trends Mol. Med. 2003, 9, 11-18. [CrossRef]
20. Prakash, O.; Kumar, A.; Kumar, P. Anticancer potential of plants and natural products: A review. Am. J. Pharmacol. Sci. 2013, 1, 104-115. [CrossRef]
21. Millimouno, F.M.; Dong, J.; Yang, L.; Li, J.; Li, X. Targeting apoptosis pathways in cancer and perspectives with natural compounds from Mother Nature. Cancer Prev. Res. 2014, 7, 1081-1107. [CrossRef] [PubMed]
22. Fulda, S. Evasion of apoptosis as a cellular stress response in cancer. Int. J. Cell Biol. 2010. [CrossRef] [PubMed]
23. Davis, J.N.; Kucuk, O.; Sarkar, F.H. Genistein inhibits NF-κB activation in prostate cancer cells. Nutr. Cancer 1999, 35, 167-174. [CrossRef] [PubMed]
24. Stephens, F.O. The rising incidence of breast cancer in women and prostate cancer in men. Dietary influences: A possible preventive role for nature’s sex hormone modifiers-the phytoestrogens (review). Oncol. Rep. 1999, 6, 865-935. [CrossRef] [PubMed]
25. Mangal, M.; Sagar, P.; Singh, H.; Raghava, G.P.; Agarwal, S.M. NPACT: Naturally occurring plant-based anti-cancer compound-activity-target database. Nucleic Acids Res. 2013, 41, D1124-D1129. [CrossRef] [PubMed]
26. Zhou, X.; Seto, S.W.; Chang, D.; Kiat, H.; Razmovski-Naumovski, V.; Chan, K.; Bensoussan, A. Synergistic effects of Chinese herbal medicine: A comprehensive review of methodology and current research. Front. Pharmacol. 2016, 7, 201. [CrossRef] [PubMed]
27. Liu, J.;Wang, S.; Zhang, Y.; Fan, H.T.; Lin, H.S. Traditional Chinese medicine and cancer: History, present situation, and development. Thorac. Cancer 2015, 6, 561-569. [CrossRef] [PubMed]
28. Chang, R. Bioactive polysaccharides from traditional Chinese medicine herbs as anticancer adjuvants. J. Altern. Complement. Med. 2002, 8, 559-565. [CrossRef] [PubMed]
29. Ni, Y.H.; Li, X.; Xu, Y.; Liu, J.P. Chinese herbal medicine for advanced pancreatic cancer. Cochrane Libr. 2012. [CrossRef]
30. Zhang, M.; Liu, X.; Li, J.; He, L.; Tripathy, D. Chinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patients. Cochrane Libr. 2007. [CrossRef]
31. Guo, Z.; Jia, X.; Liu, J.P.; Liao, J.; Yang, Y. Herbal medicines for advanced colorectal cancer. Cochrane Libr. 2012. [CrossRef]
32. Shoemaker, M.; Hamilton, B.; Dairkee, S.H.; Cohen, I.; Campbell, M.J. In vitro anticancer activity of twelve Chinese medicinal herbs. Phytother. Res. 2005, 19, 649-651. [CrossRef] [PubMed]
33. Chen, H.-H.; Zhou, H.-J.; Fang, X. Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. Pharmacol. Res. 2003, 48, 231-236. [CrossRef]
34. Sun, M.; Cao, H.; Sun, L.; Dong, S.; Bian, Y.; Han, J.; Zhang, L.; Ren, S.; Hu, Y.; Liu, C. Antitumor activities of kushen: Literature review. Evid. Based Complement. Altern. Med. 2012. [CrossRef] [PubMed]
35. Liu, J.; Henkel, T. Traditional Chinese medicine (TCM): Are polyphenols and saponins the key ingredients triggering biological activities? Curr. Med. Chem. 2002, 9, 1483-1485. [CrossRef] [PubMed]
36. Hartwell, J. Types of anticancer agents isolated from plants. Cancer Treat. Rep. 1976, 60, 1031-1067. [PubMed]
37. Lu, J.-J.; Bao, J.-L.; Chen, X.-P.; Huang, M.;Wang, Y.-T. Alkaloids isolated from natural herbs as the anticancer agents. Evid. Based Complement. Altern. Med. 2012. [CrossRef] [PubMed]
38. Yu, H.-H.; Kim, K.-J.; Cha, J.-D.; Kim, H.-K.; Lee, Y.-E.; Choi, N.-Y.; You, Y.-O. Antimicrobial activity of berberine alone and in combination with ampicillin or oxacillin against methicillin-resistant Staphylococcus aureus. J. Med. Food 2005, 8, 454-461. [CrossRef] [PubMed]
39. Han, J.; Lin, H.; Huang, W. Modulating gut microbiota as an anti-diabetic mechanism of berberine. Med. Sci. Monit. Basic Res. 2011, 17, RA164-RA167. [CrossRef]
40. Ji, Y. Active Ingredients of Traditional Chinese Medicine: Pharmacology and Application; People’s Medical Publishing House Cp., LTD: Shelton, CT, USA, 2011.
41. Moudi, M.; Go, R.; Yien, C.Y.S.; Nazre, M. Vinca alkaloids. Int. J. Prev. Med. 2013, 4, 1231-1235. [PubMed]
42. Liu, Y.; Xu, Y.; Ji, W.; Li, X.; Sun, B.; Gao, Q.; Su, C. Anti-tumor activities of matrine and oxymatrine: Literature review. Tumor Biol. 2014, 35, 5111-5119. [CrossRef] [PubMed]
43. Liang, C.Z.; Zhang, J.K.; Shi, Z.; Liu, B.; Shen, C.Q.; Tao, H.M. Matrine induces caspase-dependent apoptosis in human osteosarcoma cells in vitro and in vivo through the upregulation of Bax and Fas/FasL and downregulation of Bcl-2. Cancer Chemother. Pharmacol. 2012, 69, 317-331. [CrossRef] [PubMed]
44. Yu, P.; Liu, Q.; Liu, K.; Yagasaki, K.;Wu, E.; Zhang, G. Matrine suppresses breast cancer cell proliferation and invasion via VEGF-Akt-NF-κB signaling. Cytotechnology 2009, 59, 219-229. [CrossRef] [PubMed]
45. Zhou, K.; Ji, H.; Mao, T.; Bai, Z. Effects of matrine on the proliferation and apoptosis of human medulloblastoma cell line D341. Int. J. Clin. Exp. Med. 2014, 7, 911-918. [PubMed]
46. Xie, S.-B.; He, X.-X.; Yao, S.-K. Matrine-induced autophagy regulated by p53 through AMP-activated protein kinase in human hepatoma cells. Int. J. Oncol. 2015, 47, 517-526. [CrossRef] [PubMed]
47. Mariño, G.; Niso-Santano, M.; Baehrecke, E.H.; Kroemer, G. Self-consumption: The interplay of autophagy and apoptosis. Nat. Rev. Mol. Cell Biol. 2014, 15, 81-94. [CrossRef] [PubMed]
48. Rambold, A.S.; Cohen, S.; Lippincott-Schwartz, J. Fatty acid trafficking in starved cells: Regulation by lipid droplet lipolysis, autophagy, and mitochondrial fusion dynamics. Dev. Cell 2015, 32, 678-692. [CrossRef] [PubMed]
49. Estrela, J.M.; Ortega, A.; Obrador, E. Glutathione in cancer biology and therapy. Crit. Rev. Clin. Lab. Sci. 2006, 43, 143-181. [CrossRef] [PubMed]
50. Zou, J.; Ran, Z.H.; Xu, Q.; Xiao, S.D. Experimental study of the killing effects of oxymatrine on human colon cancer cell line SW1116. Chin. J. Dig. Dis. 2005, 6, 15-20. [CrossRef] [PubMed]
51. Wu, X.-S.; Yang, T.; Gu, J.; Li, M.-L.; Wu, W.-G.; Weng, H.; Ding, Q.; Mu, J.-S.; Bao, R.-F.; Shu, Y.-J. Effects of oxymatrine on the apoptosis and proliferation of gallbladder cancer cells. Anti Cancer drugs 2014, 25, 1007-1015. [CrossRef] [PubMed]
52. Jin, N.; Zhao, Y.-X.; Deng, S.-H.; Sun, Q. Preparation and in vitro anticancer activity of oxymatrine mixed micellar nanoparticles. Die Pharm. Int. J. Pharm. Sci. 2011, 66, 506-510.
53. Wang, B.; Han, Q.; Zhu, Y. Oxymatrine inhibited cell proliferation by inducing apoptosis in human lung cancer A549 cells. Bio Med. Mater. Eng. 2015, 26, 165-172. [CrossRef] [PubMed]
54. Li, M.; Su, B.-S.; Chang, L.-H.; Gao, Q.; Chen, K.-L.; An, P.; Huang, C.; Yang, J.; Li, Z.-F. Oxymatrine induces apoptosis in human cervical cancer cells through guanine nucleotide depletion. Anti Cancer Drugs 2014, 25, 161-173. [CrossRef] [PubMed]
55. Wu, J.-M.; Chen, Y.; Chen, J.-C.; Lin, T.-Y.; Tseng, S.-H. Tetrandrine induces apoptosis and growth suppression of colon cancer cells in mice. Cancer Lett. 2010, 287, 187-195. [CrossRef] [PubMed]
56. Qin, R.; Shen, H.; Cao, Y.; Fang, Y.; Li, H.; Chen, Q.; Xu, W. Tetrandrine induces mitochondria-mediated apoptosis in human gastric cancer BGC-823 cells. PLoS ONE 2013, 8, e76486. [CrossRef] [PubMed]
57. Panda, D.; Jordan, M.A.; Chu, K.C.; Wilson, L. Differential effects of vinblastine on polymerization and dynamics at opposite microtubule ends. J. Biol. Chem. 1996, 271, 29807-29812. [CrossRef] [PubMed]
58. Brugières, L.; Pacquement, H.; Le Deley, M.-C.; Leverger, G.; Lutz, P.; Paillard, C.; Baruchel, A.; Frappaz, D.; Nelken, B.; Lamant, L. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: A report from the French Society of Pediatric Oncology. J. Clin. Oncol. 2009, 27, 5056-5061. [CrossRef] [PubMed]
59. Yao, L.H.; Jiang, Y.; Shi, J.; Tomas-Barberan, F.; Datta, N.; Singanusong, R.; Chen, S. Flavonoids in food and their health benefits. Plant Foods Hum. Nutr. 2004, 59, 113-122. [CrossRef] [PubMed]
60. Chahar, M.K.; Sharma, N.; Dobhal, M.P.; Joshi, Y.C. Flavonoids: A versatile source of anticancer drugs. Pharmacogn. Rev. 2011, 5, 1. [PubMed]
61. Zhou, H.; Lutterodt, H.; Cheng, Z.; Yu, L. Anti-inflammatory and antiproliferative activities of trifolirhizin, a flavonoid from Sophora flavescens roots. J. Agric. Food Chem. 2009, 57, 4580-4585. [CrossRef] [PubMed]
62. Yin, T.; Yang, G.; Ma, Y.; Xu, B.; Hu, M.; You, M.; Gao, S. Developing an activity and absorption-based quality control platform for Chinese traditional medicine: Application to Zeng-Sheng-Ping (Antitumor B). J. Ethnopharmacol. 2015, 172, 195-201. [CrossRef] [PubMed]
63. Aratanechemuge, Y.; Hibasami, H.; Katsuzaki, H.; Imai, K.; Komiya, T. Induction of apoptosis by maackiain and trifolirhizin (maackiain glycoside) isolated from sanzukon (Sophora Subprostrate Chen et T. Chen) in human promyelotic leukemia HL-60 cells. Oncol. Rep. 2004, 12, 1183-1188. [CrossRef] [PubMed]
64. Fang, H.; Chen, S.; Guo, D.; Pan, S.; Yu, Z. Proteomic identification of differentially expressed proteins in curcumin-treated MCF-7 cells. Phytomedicine 2011, 18, 697-703. [CrossRef] [PubMed]
65. Ravindran, J.; Prasad, S.; Aggarwal, B.B. Curcumin and cancer cells: How many ways can curry kill tumor cells selectively? AAPS J. 2009, 11, 495-510. [CrossRef] [PubMed]
66. Jordan, B.C.; Mock, C.D.; Thilagavathi, R.; Selvam, C. Molecular mechanisms of curcumin and its semisynthetic analogues in prostate cancer prevention and treatment. Life Sci. 2016, 152, 135-144. [CrossRef] [PubMed]
67. Nelson, K.M.; Dahlin, J.L.; Bisson, J.; Graham, J.; Pauli, G.F.;Walters, M.A. The Essential Medicinal Chemistry of Curcumin: Miniperspective. J. Med. Chem. 2017, 60, 1620-1637. [CrossRef] [PubMed]
68. Baker, M.M. Deceptive curcumin offers cautionary tale for chemists. Nature 2017, 541, 144-145. [CrossRef] [PubMed]
69. Sak, K. Site-specific anticancer effects of dietary flavonoid quercetin. Nutr. Cancer 2014, 66, 177-193. [CrossRef] [PubMed]
70. Jeong, J.H.; An, J.Y.; Kwon, Y.T.; Rhee, J.G.; Lee, Y.J. Effects of low dose quercetin: Cancer cell-specific inhibition of cell cycle progression. J. Cell. Biochem. 2009, 106, 73-82. [CrossRef] [PubMed]
71. Deng, X.-H.; Song, H.-Y.; Zhou, Y.-F.; Yuan, G.-Y.; Zheng, F.-J. Effects of quercetin on the proliferation of breast cancer cells and expression of survivin in vitro. Exp. Ther. Med. 2013, 6, 1155-1158. [PubMed]
72. Zhou, J.; Liang, S.; Fang, L.; Chen, L.; Tang, M.; Xu, Y.; Fu, A.; Yang, J.; Wei, Y. Quantitative proteomic analysis of HepG2 cells treated with quercetin suggests IQGAP1 involved in quercetin-induced regulation of cell proliferation and migration. OMICS J. Integr. Biol. 2009, 13, 93-103. [CrossRef] [PubMed]
73. Man, S.; Gao, W.; Zhang, Y.; Huang, L.; Liu, C. Chemical study and medical application of saponins as anti-cancer agents. Fitoterapia 2010, 81, 703-714. [CrossRef] [PubMed]
74. Shan, B.E.; Zeki, K.; Sugiura, T.; Yoshida, Y.; Yamashita, U. Chinese medicinal herb, Acanthopanax gracilistylus, extract induces cell cycle arrest of human tumor cells in vitro. Jpn. J. Cancer Res. 2000, 91, 383-389. [CrossRef] [PubMed]
75. Yang, J.; Qian, S.; Cai, X.; Lu,W.; Hu, C.; Sun, X.; Yang, Y.; Yu, Q.; Gao, S.P.; Cao, P. Chikusetsusaponin IVa butyl ester (CS-IVa-Be), a novel IL-6R antagonist, inhibits IL-6/STAT3 signaling pathway and induces cancer cell apoptosis. Mol. Cancer Ther. 2016, 15, 1190-1200. [CrossRef] [PubMed]
76. Lee, M.-S.; Chan, J.Y.-W.; Kong, S.-K.; Yu, B.; Eng-Choon, V.O.; Nai-Ching, H.W.; Mak Chung-Wai, T.; Fung, K.-P. Effects of polyphyllin D, a steroidal saponin in Paris polyphylla, in growth inhibition of human breast cancer cells and in xenograft. Cancer Biol. Ther. 2005, 4, 1248-1254. [CrossRef] [PubMed]
77. Raju, J.; Bird, R.P. Diosgenin, a naturally occurring furostanol saponin suppresses 3-hydroxy-3-methylglutaryl CoA reductase expression and induces apoptosis in HCT-116 human colon carcinoma cells. Cancer Lett. 2007, 255, 194-204. [CrossRef] [PubMed]
78. Chiang, C.-T.; Way, T.-D.; Tsai, S.-J.; Lin, J.-K. Diosgenin, a naturally occurring steroid, suppresses fatty acid synthase expression in HER2-overexpressing breast cancer cells through modulating Akt, mTOR and JNK phosphorylation. FEBS Lett. 2007, 581, 5735-5742. [CrossRef] [PubMed]
79. Wang, J.; Zhao, X.-Z.; Qi, Q.; Tao, L.; Zhao, Q.; Mu, R.; Gu, H.-Y.; Wang, M.; Feng, X.; Guo, Q.-L. Macranthoside B, a hederagenin saponin extracted from Lonicera macranthoides and its anti-tumor activities in vitro and in vivo. Food Chem. Toxicol. 2009, 47, 1716-1721. [CrossRef] [PubMed]
80. Shan, Y.; Guan, F.; Zhao, X.; Wang, M.; Chen, Y.; Wang, Q.; Feng, X. Macranthoside B Induces Apoptosis and Autophagy Via Reactive Oxygen Species Accumulation in Human Ovarian Cancer A2780 Cells. Nutr. Cancer 2016, 68, 280-289. [CrossRef] [PubMed]
81. Tan, C.-J.; Zhao, Y.; Goto, M.; Hsieh, K.-Y.; Yang, X.-M.; Morris-Natschke, S.L.; Liu, L.-N.; Zhao, B.-Y.; Lee, K.-H. Alkaloids from Oxytropis ochrocephala and Antiproliferative Activity of Sophoridine Derivatives Against Cancer Cell Lines. Bioorganic Med. Chem. Lett. 2015, 26, 1495-1497. [CrossRef] [PubMed]
82. Ma, Y.; Gao, H.; Liu, J.; Chen, L.; Zhang, Q.; Wang, Z. Identification and determination of the chemical constituents in a herbal preparation, Compound Kushen injection, by HPLC and LC-DAD-MS/MS. J. Liq. Chromatogr. Relat. Technol. 2014, 37, 207-220. [CrossRef]
83. Wang, W.; You, R.-L.; Qin, W.-J.; Hai, L.-N.; Fang, M.-J.; Huang, G.-H.; Kang, R.-X.; Li, M.-H.; Qiao, Y.-F.; Li, J.-W. Anti-tumor activities of active ingredients in Compound Kushen Injection. Acta Pharmacol. Sin. 2015, 36, 676-679. [CrossRef] [PubMed]
84. Polakis, P. Wnt signaling and cancer. Genes Dev. 2000, 14, 1837-1851. [CrossRef] [PubMed]
85. Xu,W.; Lin, H.; Zhang, Y.; Chen, X.; Hua, B.; Hou,W.; Qi, X.; Pei, Y.; Zhu, X.; Zhao, Z. Compound Kushen Injection suppresses human breast cancer stem-like cells by down-regulating the canonical Wnt/b-catenin pathway. J. Exp. Clin. Cancer Res. 2011, 30, 103. [CrossRef] [PubMed]
86. Guo, Y.-M.; Huang, Y.-X.; Shen, H.-H.; Sang, X.-X.; Ma, X.; Zhao, Y.-L.; Xiao, X.-H. Efficacy of Compound Kushen Injection in Relieving Cancer-Related Pain: A Systematic Review and Meta-Analysis. Evid. Based Complement. Altern. Med. 2015. [CrossRef] [PubMed]
87. Qu, Z.; Cui, J.; Harata-Lee, Y.; Aung, T.N.; Feng, Q.; Raison, J.; Kortschak, R.D.; Adelson, D.L. Identification of Candidate Anti-Cancer Molecular Mechanisms Of Compound Kushen Injection Using Functional Genomics. Oncotarget 2016, 7, 66003-66019. [CrossRef] [PubMed]
88. Xudong, L.; Yan, L.; Xi, Y.; Xiaoguang, W.; Xiaoguang, H. Long noncoding RNA H19 regulates EZH2 expression by interacting with miR-630 and promotes cell invasion in nasopharyngeal carcinoma. Biochem. Biophys. Res. Commun. 2016, 473, 913-919.
89. Zhang, Z.; Wang, Y.; Yao, R.; Li, J.; Yan, Y.; La Regina, M.; Lemon,W.L.; Grubbs, C.J.; Lubet, R.A.; You, M. Cancer chemopreventive activity of a mixture of Chinese herbs (antitumor B) in mouse lung tumor models. Oncogene 2004, 23, 3841-3850. [CrossRef] [PubMed]
90. Guan, X.; Sun, Z.; Chen, X.; Wu, H.; Zhang, X. Inhibitory effects of Zengshengping fractions on DMBA-induced buccal pouch carcinogenesis in hamsters. Chin. Med. J. 2012, 125, 332-337. [CrossRef] [PubMed]
91. Lim, K.J.; Rajan, K.; Eberhart, C.G. Effects of Zeng Sheng Ping/ACAPHA on Malignant Brain Tumor Growth and Notch Signaling. Anticancer Res. 2012, 32, 2689-2696. [PubMed]
92. Sun, Z.; Guan, X.; Li, N.; Liu, X.; Chen, X. Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncol. 2010, 46, 105-110. [CrossRef] [PubMed]
93. Voyno-Yasenetskaya, T.A.; Pace, A.M.; Bourne, H.R. Mutant alpha subunits of G12 and G13 proteins induce neoplastic transformation of Rat-1 fibroblasts. Oncogene 1994, 9, 2559-2565. [PubMed]
94. Berestetskaya, Y.V.; Faure, M.P.; Ichijo, H.; Voyno-Yasenetskaya, T.A. Regulation of apoptosis by α-subunits of G12 and G13 proteins via apoptosis signal-regulating kinase-1. J. Biol. Chem. 1998, 273, 27816-27823. [CrossRef] [PubMed]
95. Tian, Z.H.; Li, Z.F.; Zhou, S.B.; Liang, Y.Y.; He, D.C.; Wang, D.S. Differentially expressed proteins of MCF-7 human breast cancer cells affected by Zilongjin, a complementary Chinese herbal medicine. Proteom. Clin. Appl. 2010, 4, 550-559. [CrossRef] [PubMed]
96. Zhang, P.;Wang, X.; Xiong, S.;Wen, S.; Gao, S.;Wang, L.; Cao, B. Genome wide expression analysis of the effect of the Chinese patent medicine zilongjin tablet on four human lung carcinoma cell lines. Phytother. Res. 2011, 25, 1472-1479. [CrossRef] [PubMed]
97. Huang, L.-C.; Clarkin, K.C.;Wahl, G.M. Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest. Proc. Natl. Acad. Sci. USA 1996, 93, 4827-4832. [CrossRef] [PubMed]
98. Wang, Y.; Wang, J.; Yao, M.; Zhao, X.; Fritsche, J.; Schmitt-Kopplin, P.; Cai, Z.; Wan, D.; Lu, X.; Yang, S. Metabonomics study on the effects of the ginsenoside Rg3 in a β-cyclodextrin-based formulation on tumor-bearing rats by a fully automatic hydrophilic interaction/reversed-phase column-switching HPLC-ESI-MS approach. Anal. Chem. 2008, 80, 4680-4688. [CrossRef] [PubMed]
99. Bayet-Robert, M.; Morvan, D. Metabolomics reveals metabolic targets and biphasic responses in breast cancer cells treated by curcumin alone and in association with docetaxel. PLoS ONE 2013, 8, e57971. [CrossRef] [PubMed]
100. Li, Z.; Zheng, L.; Shi, J.; Zhang, G.; Lu, L.; Zhu, L.; Zhang, J.; Liu, Z. Toxic Markers of Matrine Determined Using 1H-NMR-Based Metabolomics in Cultured Cells In Vitro and Rats In Vivo. Evid. Based Complement. Altern. Med. 2015. [CrossRef]
101. Yue, Q.-X.; Song, X.-Y.; Ma, C.; Feng, L.-X.; Guan, S.-H.;Wu,W.-Y.; Yang, M.; Jiang, B.-H.; Liu, X.; Cui, Y.-J. Effects of triterpenes from Ganoderma lucidum on protein expression profile of HeLa cells. Phytomedicine 2010, 17, 606-613. [CrossRef] [PubMed]
102. Wei, D.-F.; Wei, Y.-X.; Cheng, W.-D.; Yan, M.-F.; Su, G.; Hu, Y.; Ma, Y.-Q.; Han, C.; Lu, Y.; Hui-Ming, C. Proteomic analysis of the effect of triterpenes from Patrinia heterophylla on leukemia K562 cells. J. Ethnopharmacol. 2012, 144, 576-583. [CrossRef] [PubMed]
103. Singh, C.K.; Kaur, S.; George, J.; Nihal, M.; Hahn, M.C.P.; Scarlett, C.O.; Ahmad, N. Molecular signatures of sanguinarine in human pancreatic cancer cells: A large scale label-free comparative proteomics approach. Oncotarget 2015, 6, 10335. [CrossRef] [PubMed]
104. Zhang, H.; Zhou, Q.-M.; Lu, Y.-Y.; Jia, D.; Su, S.-B. Aidi Injection () Alters the Expression Profiles of MicroRNAs in Human Breast Cancer Cells. J. Tradit. Chin. Med. 2011, 31, 10-16. [CrossRef]
105. Dyson, P.J.; Sava, G. Metal-based antitumour drugs in the post genomic era. Dalton Trans. 2006, 1929-1933. [CrossRef] [PubMed]
106. Chen, Z.-F.; Liang, H.; Liu, Y.-C. Traditional Chinese Medicine Active Ingredient-Metal Based Anticancer Agents; INTECH Open Access Publisher: Rijeka, Croatia, 2012.
107. Dholwani, K.; Saluja, A.; Gupta, A.; Shah, D. A review on plant-derived natural products and their analogs with anti-tumor activity. Indian J. Pharmacol. 2008, 40, 49-58. [CrossRef]
108. Chen, Z.-F.; Mao, L.; Liu, L.-M.; Liu, Y.-C.; Peng, Y.; Hong, X.;Wang, H.-H.; Liu, H.-G.; Liang, H. Potential new inorganic antitumour agents from combining the anticancer traditional Chinese medicine (TCM) matrine with Ga (III), Au (III), Sn (IV) ions, and DNA binding studies. J. Inorg. Biochem. 2011, 105, 171-180. [CrossRef]
109. Tan, C.;Wu, S.; Lai, S.;Wang, M.; Chen, Y.; Zhou, L.; Zhu, Y.; Lian,W.; Peng,W.; Ji, L. Synthesis, structures, cellular uptake and apoptosis-inducing properties of highly cytotoxic ruthenium-Norharman complexes. Dalton Trans. 2011, 40, 8611-8621. [CrossRef] [PubMed]
110. Chen, Z.-F.; Liu, Y.-C.; Huang, K.-B.; Liang, H. Alkaloid-metal based anticancer agents. Curr. Top. Med. Chem. 2013, 13, 2104-2115. [CrossRef]
111. Tan, M.; Zhu, J.; Pan, Y.; Chen, Z.; Liang, H.; Liu, H.;Wang, H. Synthesis, cytotoxic activity, and DNA binding properties of copper (II) complexes with hesperetin, naringenin, and apigenin. Bioinorg. Chem. Appl. 2009. [CrossRef] [PubMed]
112. Tan, J.; Wang, B.; Zhu, L. DNA binding and oxidative DNA damage induced by a quercetin copper (II) complex: Potential mechanism of its antitumor properties. JBIC J. Biol. Inorg. Chem. 2009, 14, 727-739. [CrossRef] [PubMed]
113. Glavinas, H.; Krajcsi, P.; Cserepes, J.; Sarkadi, B. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr. Drug Deliv. 2004, 1, 27-42. [CrossRef] [PubMed]
114. Liu, Y.; Peng, H.; Zhang, J.-T. Expression profiling of ABC transporters in a drug-resistant breast cancer cell line using AmpArray. Mol. Pharmacol. 2005, 68, 430-438. [CrossRef] [PubMed]
115. Park, S.; Shimizu, C.; Shimoyama, T.; Takeda, M.; Ando, M.; Kohno, T.; Katsumata, N.; Kang, Y.-K.; Nishio, K.; Fujiwara, Y. Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res. Treat. 2006, 99, 9-17. [CrossRef] [PubMed]
116. Sasaki, N.; Ishii, T.; Kamimura, R.; Kajiwara, M.; Machimoto, T.; Nakatsuji, N.; Suemori, H.; Ikai, I.; Yasuchika, K.; Uemoto, S. Alpha-fetoprotein-producing pancreatic cancer cells possess cancer stem cell characteristics. Cancer Lett. 2011, 308, 152-161. [CrossRef] [PubMed]
117. Kioka, N.; Hosokawa, N.; Komano, T.; Hirayoshi, K.; Nagate, K.; Ueda, K. Quercetin, a bioflavonoid, inhibits the increase of human multidrug resistance gene (MDR1) expression caused by arsenite. FEBS Lett. 1992, 301, 307-309. [CrossRef]
118. Cai, X.; Chen, F.; Han, J.; Gu, C.; Zhong, H.; Ouyang, R. Restorative effect of quercetin on subcellular distribution of daunorubicin in multidrug resistant leukemia cell lines K562/ADM and HL-60/ADM. Chin. J. Cancer 2004, 23, 1611-1615.
119. Cai, X.; Chen, F.; Han, J.; Gu, C.; Zhong, H.; Teng, Y.; Ouyang, R. Reversal of multidrug resistance of HL-60 adriamycin resistant leukemia cell line by quercetin and its mechanisms. Chin. J. Oncol. 2005, 27, 326-329.
120. Tang, X.-Q.; Bi, H.; Feng, J.-Q.; Cao, J.-G. Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR. Acta Pharmacol. Sin. 2005, 26, 1009-1016. [CrossRef] [PubMed]
121. Ganta, S.; Amiji, M. Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol. Pharm. 2009, 6, 928-939. [CrossRef] [PubMed]
122. Fix, L.N.; Shah, M.; Efferth, T.; Farwell, M.A.; Zhang, B. MicroRNA expression profile of MCF-7 human breast cancer cells and the effect of green tea polyphenon-60. Cancer Genom. Proteom. 2010, 7, 261-277.
123. Kasinski, A.L.; Slack, F.J. MicroRNAs en route to the clinic: Progress in validating and targeting microRNAs for cancer therapy. Nat. Rev. Cancer 2011, 11, 849-864. [CrossRef] [PubMed]
124. Miller, T.E.; Ghoshal, K.; Ramaswamy, B.; Roy, S.; Datta, J.; Shapiro, C.L.; Jacob, S.; Majumder, S. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J. Biol. Chem. 2008, 283, 29897-29903. [CrossRef] [PubMed]
125. Kovalchuk, O.; Filkowski, J.; Meservy, J.; Ilnytskyy, Y.; Tryndyak, V.P.; Vasyl’F, C.; Pogribny, I.P. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol. Cancer Ther. 2008, 7, 2152-2159. [CrossRef] [PubMed]
126. Mani, S.A.; Guo, W.; Liao, M.-J.; Eaton, E.N.; Ayyanan, A.; Zhou, A.Y.; Brooks, M.; Reinhard, F.; Zhang, C.C.; Shipitsin, M. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133, 704-715. [CrossRef] [PubMed]
127. Angst, B.D.; Marcozzi, C.; Magee, A.I. The cadherin superfamily. J. Cell Sci. 2001, 114, 625-626. [PubMed]
128. Hurteau, G.J.; Carlson, J.A.; Spivack, S.D.; Brock, G.J. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res. 2007, 67, 7972-7976. [CrossRef] [PubMed]
129. Adam, L.; Zhong, M.; Choi, W.; Qi, W.; Nicoloso, M.; Arora, A.; Calin, G.; Wang, H.; Siefker-Radtke, A.; McConkey, D. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin. Cancer Res. 2009, 15, 5060-5072. [CrossRef] [PubMed]
130. Lin, Y.; Lin, L.; Jin, Y.; Zhang, Y.; Wang, D.; Tan, Y.; Zheng, C. Combination of Matrine and Sorafenib Decreases the Aggressive Phenotypes of Hepatocellular Carcinoma Cells. Chemotherapy 2014, 60, 112-118. [CrossRef] [PubMed]
131. Li, H.; Xie, S.; Liu, X.;Wu, H.; Lin, X.; Gu, J.;Wang, H.; Duan, Y. Matrine alters microRNA expression profiles in SGC-7901 human gastric cancer cells. Oncol. Rep. 2014, 32, 2118-2126. [CrossRef] [PubMed]
132. Li, J.; Jiang, K.; Zhao, F. Oxymatrine suppresses proliferation and facilitates apoptosis of human ovarian cancer cells through upregulating microRNA-29b and downregulating matrix metalloproteinase-2 expression. Mol. Med. Rep. 2015, 12, 5369-5374. [CrossRef] [PubMed]
133. Wang, Z.; Wang, N.; Liu, P.; Chen, Q.; Situ, H.; Xie, T.; Zhang, J.; Peng, C.; Lin, Y.; Chen, J. MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells, a process modulated by the natural autophagy inducer isoliquiritigenin. Oncotarget 2014, 5, 7013-7026. [CrossRef] [PubMed]
134. Luo, S.; Deng, W.; Wang, X.; Lü, H.; Han, L.; Chen, B.; Chen, X.; Li, N. Molecular mechanism of indirubin-30-monoxime and Matrine in the reversal of paclitaxel resistance in NCI-H520/TAX25 cell line. Chin. Med. J. 2013, 126, 925-929. [PubMed]
135. Schmitt, C.A.; Lowe, S.W. Apoptosis and chemoresistance in transgenic cancer models. J. Mol. Med. 2002, 80, 137-146. [CrossRef] [PubMed]